| > Dr Bruno Larrivée
Dr Bruno Larrivée
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont
5415, Boulevard de l'Assomption
Montréal, QC H1T 2M3
Tel: 1-514-252-3400, ext. 7740
- Vascular Integrity
- Retinal Blood Vessels
- BMP signaling
- Diabetic Retinopathies
- Vascular Normalization
Bruno Larrivée, PhD
Assistant Professor of Ophthalmology
Bruno Larrivée was trained in Experimental Medicine at the University of
British Columbia, where he obtained a PhD degree. His thesis was in the field
of vascular development in tumors and VEGF signaling in hematopoietic cells under
the direction of Dr Aly Karsan. He then joined the laboratory of Dr Anne Eichmann
in Collège de France in Paris, where he worked as a post-doctoral fellow on axon
guidance molecules, and how they influence the patterning of blood vessels. After
working for Medimmune/AstraZeneca in Cambridge for 2 years, he joined the Yale
Cardiovascular Research Center in 2010 as research associate, where he worked on
deciphering the role of BMP signaling during vascular development. In 2013, he
joined the Ophthalmology department of Université de Montréal as assistant professor.
His research focuses on factors that mediate the quiescence and integrity of blood
vessels during physiological and pathological angiogenesis.
Click here for pdf CV
Selected Scientific Contributions
Dr Larrivée has described the roles of Netrins, which are axon guidance molecules
involved in the proper patterning of neural connections, in the development of the
cardiovascular system. Using experimental models of developmental and pathological
vascular development, he has shown that one of the Netrin receptor, Unc5B, is
specifically expressed in the endothelium, and that it mediates the proper patterning
of blood vessels in part through its guidance effects, and by modulating the response
of endothelial cells to VEGF.
The recent research of Dr Larrivée has focused on the role of vascular quiescence
factors, and how they help maintain the integrity of blood vessels. Specifically,
he has shown that BMP and Notch signaling collaborate to help maintain stable blood
vessels. He has shown that in pathological conditions, such as in retinopathies,
promoting BMP signaling help prevent the formation of neovessels and limits VEGF
Click here for PubMed listing
Induction of the formation of new blood vessels (angiogenesis) in the eye is frequently
associated with various disorders, which can cause severe loss of vision and can lead
to blindness. Among these disorders, diabetic retinopathy and age-related macular
degeneration are among the most prevalent in the western world. Current therapies
against excessive ocular angiogenesis include laser surgery or inhibition of Vascular
Endothelial Growth Factor (VEGF), a factor with important pro-angiogenic properties.
However, the identification of alternative pathways that regulate angiogenesis may
lead to the development of inhibitors more effective and safer for ocular angiogenesis.
Dr Larrivée’s laboratory studies developmental and pathological angiogenesis in order
to identify new signaling pathways controlling the formation and morphogenesis of blood
vessels. Specifically, three main research areas are covered: 1) Evaluation of signaling
pathways that modulate the response of endothelial cells to VEGF; 2) Development of
strategies to promote vascular normalization in tumor vessels to increase the perfusion
of therapeutic drugs; 3) Investigation of the effects of hyperglycemia on endothelial
cells, in order to develop strategies to prevent vascular leakage associated with macular
edema in diabetic patients.
The research team uses a wide range of technologies including rodent KO models, RNA
silencing, metabolomics/proteomics and transcriptomics to address these specific issues.